The Cooper Companies’ COO second-quarter fiscal 2018 results are scheduled to release on Jun 7, after market close. While the core CooperVision (CVI) division is likely to put up a stellar performance, growth across other major segments may also act as catalysts.
In the fiscal first quarter, Cooper Companies posted strong results, with adjusted earnings of $2.79 per share beating the Zacks Consensus Estimate by 10.7% and increasing 44.6% year over year.
Moreover, revenues in the first quarter increased 4% at constant currency (cc) to $590 million, also outpacing the Zacks Consensus Estimate of $582.1 million.
Notably, for the second quarter, the Zacks Consensus Estimate for revenues is pegged at $626.6 million, reflecting year-over-year growth of 19.9%. The same for adjusted earnings per share is pinned at $2.83, showing year-over-year growth of 13.2%.
Furthermore, for the trailing four quarters, Cooper Companies has a positive earnings surprise of 6.1%.
The Cooper Companies, Inc. Price and EPS Surprise
The Cooper Companies, Inc. Price and EPS Surprise | The Cooper Companies, Inc. Quote
Let’s delve deeper.
CooperVision in Focus
CooperVision manufactures and sells a wide range of contact lenses. In the last reported quarter, this segment accounted for a whopping 75.4% of Cooper Companies’ revenues. Revenues in the segment came in at $444.8 million, up 8% at cc.
Robust performance by toric (31% of CVI revenues), multifocal (11%), single-use sphere lenses (26%) and non-single-use sphere lenses (32%) drove solid growth in the segment.
Notably, for the second quarter, the Zacks Consensus Estimate for CVI revenues are pinned at $464 million which shows a year-over-year increase of 13.4%.
Multifocal revenues rose 5% year over year at cc to $46.9 million. The Zacks Consensus Estimate for second-quarter revenues is pegged at $47.4 million, reflecting a rise of 10.6% from a year ago.
Toric revenues increased 9% to $137.8 million. The consensus estimate for second-quarter revenues is pegged at $148 million, indicating a year-over-year upside of 12.1%.
Single-use sphere lenses sales climbed 11% at cc to $116.3 million. The Zacks Consensus Estimate for second-quarter revenues stands at $119 million, showing a year-over-year rise of 14.4%.
Sales of non-single-use sphere lenses rose 4% to $143.8 million. The Zacks Consensus Estimate for second-quarter revenues is pinned at $147 million, showing year-over-year growth of 13.1%.
Other Factors at Play
CooperSurgical (CSI)
CooperSurgical offers a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. In the first quarter of fiscal 2018, the segment accounted for 24.6% of total revenues. Meanwhile, the Zacks Consensus Estimate for the segment’s second-quarter revenues is pegged at $162 million, indicating growth of 42.1% from the prior-year quarter. Management is also optimistic about the recently-closed acquisition of PARAGARD.
The fertility category posted revenues of $57 million, down 5% at cc. However, the Zacks Consensus Estimate for the segment is pegged at $63 million, up from $61 million recorded in the prior-year quarter. Recently, Cooper Companies acquired the assets of The LifeGlobal Group and its affiliates, which is likely to augment its fertility business.
Guidance Solid
For fiscal 2018, total revenues are projected in the band of $2,510-$2,560 million compared with the previous $2,480-$2,530 million.
Revenues at the CVI segment are now estimated in the range of $1,865-$1,900 million, higher than the earlier $1,830-$1,865 million.
Adjusted earnings per share are now anticipated in the band of $11.70-$11.90 versus $11.35-$11.65 earlier.
Intense Competition
Cooper Companies operates in a highly competitive industry. Both of the company’s business segments face considerable competition from peers. CooperVision primarily faces competition in the spherical, toric and multifocal lens categories from the likes of Johnson & Johnson Vision Care, CIBA Vision owned by Novartis AG and Valeant Pharmaceuticals’ Bausch & Lomb.
What Our Model Predicts
Our quantitative model does not conclusively predict a beat for Cooper Companies this earnings season. This is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates.
Zacks ESP: The Earnings ESP for Cooper Companies is -0.45%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Cooper Companies carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few stocks worth considering as they have the right combination of elements to post beats this earnings season.
AbbVie Inc. ABBV has an Earnings ESP of +0.25% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Ally Financial Inc. ALLY has an Earnings ESP of +3.14% and a Zacks Rank #3.
American Tower Corporation AMT has an Earnings ESP of +0.02% and a Zacks Rank #3.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment